Every Form 4 that Guardant Health, Inc. (GH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GH filings page.
Guardant Health director Tariq Musa reported a routine equity compensation transaction. On February 15, 2026, he exercised or converted 250 Restricted Stock Units at $0 into 250 shares of Guardant Health common stock.
Following this derivative conversion, Musa directly holds 8,493 shares of common stock and 3,248 Restricted Stock Units. The RSUs were part of an award granted on March 6, 2023 that vests over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the next three years.
Guardant Health director Steve Krognes reported a routine equity compensation event. On January 31, 2026, 154 Restricted Stock Units vested at an exercise price of $0, resulting in the acquisition of 154 shares of common stock. Following this transaction, he directly holds 18,899 shares of common stock and 772 Restricted Stock Units.
The vested RSUs come from an award granted on August 9, 2022, which vested 25% of the shares on June 30, 2023. The remaining 75% vests in substantially equal monthly installments over the three years after June 30, 2023.
Guardant Health Chief People Officer Terilyn J. Monroe reported multiple open-market sales of company stock. On January 21, 2026, she sold 1,703 shares of Guardant Health common stock at a weighted average price of $112.3418 per share, 3,619 shares at a weighted average price of $113.4793 per share, and 3,249 shares at a weighted average price of $115.6978 per share. Each sale was executed in multiple transactions within disclosed price ranges. After these sales, Monroe directly beneficially owned 20,990 shares of Guardant Health common stock.
Guardant Health director Roberto Mignone reported a routine vesting of equity awards. On 01/21/2026, 264 Restricted Stock Units converted into 264 shares of Guardant Health common stock at an exercise price of $0 per share, increasing his directly held common stock to 3,959 shares. The related RSU award, granted on November 8, 2024, vests over four years: 25% of the shares vested on the one-year anniversary of 10/21/2024, and the remaining 75% vests in equal monthly installments over the following three years. After this vesting event, Mignone directly holds 8,712 RSUs in addition to his common shares.
Guardant Health director Manuel Hidalgo Medina reported a routine equity award vesting. On January 17, 2026, 232 Restricted Stock Units converted at an exercise price of $0 into 232 shares of common stock. After this transaction, he beneficially owned 1,261 shares of common stock directly and 6,961 Restricted Stock Units.
The Restricted Stock Units were granted on July 17, 2024 and vest over four years. 25% of the award vested on the one-year anniversary of that grant date, and the remaining 75% vests in equal monthly installments over the following three years.
Guardant Health director Musa Tariq reported the vesting and conversion of 250 restricted stock units into 250 shares of common stock at a price of $0 per share on January 15, 2026. Following this transaction, he directly owns 8,243 shares of Guardant Health common stock and 3,498 restricted stock units. The RSUs were granted on March 6, 2023 and vest over four years: 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the subsequent three-year period.
Guardant Health reported that Chief People Officer Terilyn J. Monroe had 17,379 Restricted Stock Units settle into 17,379 shares of Common Stock on January 15, 2026. Of these, 8,808 shares were retained by the company at $111.98 per share to satisfy tax withholding obligations, and she now holds 29,561 shares of Common Stock directly. The underlying RSU award was granted on February 26, 2024 and vests 33% on the one-year anniversary of January 15, 2024, with the remaining 67% vesting annually over the following two-year period.
Guardant Health’s Chief People Officer, Terilyn J. Monroe, reported selling common stock in three transactions on January 7, 2026. She sold 6,311 shares at a weighted average price of $111.7521 per share, 3,632 shares at $112.6182 per share, and 88 shares at $113.4397 per share. After these sales, she held 20,990 shares of Guardant Health common stock directly. The prices reported are weighted averages for multiple trades within disclosed price ranges.
Guardant Health, Inc. director reports RSU vesting and share acquisition. On 12/17/2025, reporting person Manuel Hidalgo Medina acquired 232 shares of Guardant Health common stock at a price of $0 through the settlement of previously granted restricted stock units, reported with transaction code M.
The restricted stock units were granted on July 17, 2024 and vest over four years, with 25% of the shares vesting on the one-year anniversary of that date and the remaining 75% vesting monthly over the following three years. After this transaction, the reporting person beneficially owns 1,029 shares of common stock directly and 7,193 restricted stock units.
Guardant Health, Inc. director Musa Tariq disclosed a small sale of company stock. On 12/17/2025, the reporting person sold 116 shares of Guardant Health common stock at a price of $101.46 per share. After this transaction, the director beneficially owned 7,993 shares of Guardant Health common stock, held in direct ownership. This filing is a routine insider ownership update and does not describe any additional transactions or derivative securities.
Guardant Health, Inc. director reports routine vesting of restricted stock units. On 12/15/2025, a reporting person who serves as a director of Guardant Health, Inc. (ticker GH) acquired 250 shares of common stock at a price of $0 through the vesting and settlement of previously granted restricted stock units. After this transaction, the director beneficially owned 8,109 shares of common stock directly and 3,748 restricted stock units that remain outstanding.
The restricted stock units were originally granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting in equal monthly installments over the following three-year period.
Guardant Health, Inc. Chief Legal Officer John G. Saia reported equity compensation activity on December 15, 2025. 1,020 Restricted Stock Units converted into common stock at $0 per share, and 535 common shares were withheld by the company to meet tax withholding obligations at $102.67 per share, as explained in a footnote. After these transactions he directly holds 43,657 shares of Guardant Health common stock.
Guardant Health, Inc. (GH) disclosed an insider equity transaction by its Chief Information Officer, Kumud Kalia. On 12/15/2025, 637 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of restricted stock units. On the same date, 323 shares were disposed of at $102.67 per share, with the company retaining these shares to satisfy tax withholding obligations related to the vesting. After these transactions, the reporting person beneficially owned 22,679 shares of common stock directly, along with 1,275 restricted stock units that remain outstanding and subject to future vesting.
Guardant Health, Inc. reported an insider stock transaction by its Chief Commercial Officer. On December 15, 2025, the officer acquired 1,402 shares of common stock at $0 when a portion of a restricted stock unit (RSU) award vested. On the same date, 594 shares were withheld and disposed of at $102.67 per share to cover tax withholding obligations, as explained in the footnotes.
After these transactions, the officer directly owned 26,795 shares of Guardant Health common stock. The RSU award was originally granted on June 9, 2023; 33% vested on June 15, 2024, and the remaining 67% is scheduled to vest in equal quarterly installments over the following two years. Following the reported transaction, 2,804 restricted stock units remained beneficially owned.
Guardant Health, Inc. Co-Chief Executive Officer and director Helmy Eltoukhy reported open-market sales of company stock. On 12/15/2025, he sold 83,945 shares of common stock at a weighted average price of $103.8012 per share, and an additional 6,620 shares at a weighted average price of $104.0224 per share. Both transactions are coded as sales. Following these trades, he beneficially owns 2,047,143 shares of Guardant Health common stock directly. The prices reflect multiple individual transactions within narrow price ranges, and detailed trade breakdowns are available upon request from the company or the reporting person.
Guardant Health, Inc. reported an insider equity transaction by its Chief Medical Officer, Craig Eagle. On 12/15/2025, 1,402 shares of common stock were acquired at an exercise price of $0 upon the vesting and settlement of previously granted restricted stock units. On the same date, 711 shares were disposed of at $102.67 per share, retained by the company to cover tax withholding obligations related to this vesting.
Following these transactions, Craig Eagle beneficially owned 45,007 shares of Guardant Health common stock directly, and held 2,804 restricted stock units as derivative securities. The underlying restricted stock unit award was granted on June 9, 2023 and vests over a three-year period, with 33% having vested on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.
Guardant Health, Inc. (GH) Chief Technology Officer Darya Chudova sold 5,451 shares of common stock on 12/15/2025 at a weighted average price of $104.0418 per share. The sale was executed through multiple transactions at prices ranging from $104.0401 to $104.0900. Following this transaction, Chudova beneficially owns 7,012 shares of Guardant Health common stock in direct ownership.
Guardant Health, Inc.'s Chief Financial Officer, Michael Brian Bell, reported equity transactions involving restricted stock units and common stock. On 12/15/2025, 1,233 and 2,039 restricted stock units were converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held common shares. On the same date, 1,659 shares of common stock were withheld and disposed of at $102.67 per share to satisfy tax withholding obligations related to the vesting, with the filing stating that the amount retained was not in excess of the tax liability. After these transactions, he directly beneficially owned 29,665 shares of common stock and held 4,078 restricted stock units that continue to vest over multi‑year schedules.
Guardant Health, Inc. reported insider equity transactions by its Chief Technology Officer, Darya Chudova, on Form 4. On 12/08/2025, 68,144 shares of common stock were transferred at no cost from her direct ownership to the Chudova Family Trust, changing the form of ownership from direct to indirect. The filing also shows two open-market sales of Guardant Health common stock on the same date: 9,271 shares sold at a weighted average price of $106.0029 per share and 13,664 shares sold at a weighted average price of $105.0371 per share, executed in multiple transactions within narrow price ranges.
After these transactions, Chudova reported beneficial ownership of 12,463 shares held directly and 54,480 shares held indirectly through the Chudova Family Trust. The disclosure notes that 488 of the shares in Table I were previously acquired under Guardant Health's Employee Stock Purchase Plan.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported a series of open-market sales of the company’s common stock on December 5, 2025. The Form 4 shows multiple sale transactions at weighted average prices including $101.4027, $102.0946, $103.2528, $103.9717, $105.9863 and $106.7081 per share, with each line representing shares sold across narrower intraday price ranges from $100.710 up to $106.990 per share. Each transaction is coded as a sale and reported as directly held. Following these sales, Freeman’s directly owned position in Guardant Health common stock is disclosed as 25,987 shares.
Guardant Health (GH) director Roberto A. Mignone reported an equity transaction involving restricted stock units and common stock. On 11/21/2025, 264 restricted stock units were converted into 264 shares of common stock at an exercise price of $0, reported under transaction code M.
Following this transaction, Mignone beneficially owned 3,431 shares of Guardant Health common stock directly and 9,240 restricted stock units. The RSU award was granted on November 8, 2024 and vests over four years: 25% of the shares vested on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) director reports small stock sale
A director of Guardant Health, Inc., identified in the signature as Musa Tariq, reported selling 116 shares of the company’s common stock on 11/19/2025. The sale, coded as an "S" transaction, was executed at a price of $96.25 per share. After this transaction, the reporting person beneficially owns 7,859 shares of Guardant Health common stock, held in direct ownership.
Guardant Health, Inc. (GH) director Manuel Hidalgo Medina reported an equity award vesting and share issuance. On 11/17/2025, 232 restricted stock units converted into 232 shares of common stock at an exercise price of $0, increasing his directly held common stock to 1,047 shares.
The transaction reflects ongoing vesting from a restricted stock unit grant awarded on July 17, 2024. That grant vests over four years, with 25% of the shares vesting on the one-year anniversary of July 17, 2024 and the remaining 75% vesting in equal monthly installments over the following three years. After this conversion, he continues to hold 7,425 restricted stock units directly.
Guardant Health, Inc. (GH) director Musa Tariq reported a routine equity transaction involving company stock. On 11/15/2025, 250 shares of Common Stock were acquired at a price of $0, following the vesting and settlement of a previously granted restricted stock unit award. After this transaction, Tariq beneficially owned 7,975 shares of Common Stock directly and held 3,998 restricted stock units directly.
The restricted stock units were granted on March 6, 2023 and vest over four years. According to the vesting schedule, 25% of the award vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the subsequent three-year period.
Guardant Health (GH) reported insider activity by director Manuel Hidalgo Medina. On 11/07/2025, he exercised 1,000 stock options at $32.55 and sold 1,500 shares in two trades at $95.1651 and $95.2301. Following these transactions, he held 815 shares directly.
The exercised option was granted on July 17, 2024 and expires on July 17, 2034. Per the award’s terms, 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years. After these transactions, he reported 16,029 derivative securities (stock options) beneficially owned.
Guardant Health (GH) reported an insider transaction by its Chief Legal Officer. On 11/07/2025, the reporting person sold 8,996 shares of common stock at a price of $96.25 per share. Following the sale, the filing shows 43,172 shares beneficially owned, held directly.
Guardant Health (GH) director Steve Krognes reported a Form 4 for an RSU conversion on 10/31/2025. A restricted stock unit vested and settled into 154 shares of common stock at a stated price of $0 (transaction code M). Following the transaction, he directly beneficially owned 18,436 shares of common stock and held 1,235 RSUs as derivative securities.
The RSU grant was made on August 9, 2022, with 25% vesting on June 30, 2023, and the remaining 75% vesting in substantially equal monthly installments over the next three years. The filing was made by one reporting person in his capacity as a Director.
Guardant Health (GH) reported an insider equity change. Director Roberto A. Mignone had 3,167 shares of Common Stock acquired on 10/21/2025 via a code M transaction, reflecting the conversion of restricted stock units at a price of $0.
Following the transaction, the filing lists 3,167 Common Stock shares beneficially owned in direct form. The derivative table shows 9,504 Restricted Stock Units beneficially owned after the event. The RSU grant from November 8, 2024 vests over four years: 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) director Manuel Hidalgo Medina reported the vesting and settlement of restricted stock units into 232 shares of Common Stock on 10/17/2025 (transaction code M) at $0 per share.
Following the transaction, he directly owned 1,315 shares of Common Stock and held 7,657 RSUs outstanding. The RSU grant dated July 17, 2024 vests over four years: 25% vested on the one-year anniversary of July 17, 2024, with the remaining 75% vesting monthly over the next three years.
Guardant Health (GH) reported an insider transaction on a Form 4. A company director sold 116 shares of common stock at $66.95 on 10/17/2025. Following the sale, the reporting person directly holds 7,725 shares.
Guardant Health (GH) filed a Form 4 disclosing an insider sale. Director Myrtle S. Potter sold 26 shares of common stock on 10/17/2025 at $66.95 per share. After this transaction, she directly beneficially owns 18,324 shares. The filing lists the ownership form as direct and does not report any derivative security activity.
Guardant Health (GH) director reports Form 4 activity. On 10/15/2025, 250 shares of common stock were acquired at $0 following the settlement of restricted stock units (transaction code M). After this transaction, the reporting person directly owns 7,841 shares.
The related derivative line shows 250 restricted stock units converted into 250 shares at $0 on 10/15/2025, leaving 4,248 derivative securities (restricted stock units) directly beneficially owned after the event.
The award referenced in the footnotes was granted on March 6, 2023 and vests over four years: 25% vested on the one-year anniversary of March 15, 2023, with the remaining 75% vesting monthly over the following three years.
Guardant Health (GH) reported an insider equity change by a director. On October 15, 2025, 69 shares of Common Stock were acquired at $0 upon the vesting and settlement of Restricted Stock Units (RSUs) (transaction code M). Following this, the director directly owned 18,350 shares.
The RSU award vested 25% on October 15, 2022, with the remaining 75% vesting in substantially equal monthly installments over the next three years.
Chris Freeman, Chief Commercial Officer of Guardant Health, Inc. (GH), reported multiple equity transactions dated 10/01/2025. He had 13,550 restricted stock units vest or be credited (1,928; 1,668; 9,954) and a separate purchase of 5,740 shares at $62.65. The company retained 5,740 shares to satisfy the tax withholding related to one vesting installment; the filer notes the retained amount did not exceed the tax liability. Following the reported transactions, Freeman beneficially owned 63,179 shares (direct ownership). The Form 4 was signed by an attorney-in-fact on behalf of Mr. Freeman on 10/02/2025.
Guardant Health director and Co‑Chief Executive Officer AmirAli Talasaz reported multiple transactions in the company's common stock. On 09/30/2025 he received 4,814 shares from vesting of restricted stock units and, separately the same day, 2,440 shares were retained by the company to satisfy tax withholding at a reported price of $62.48. On 10/01/2025 he received an additional 23,997 vested shares and 12,162 shares were retained for tax withholding at $62.65. After these reported transactions his beneficial ownership rose to 2,010,036 shares.
Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported a transaction dated 09/30/2025 in which 154 shares were acquired following vesting of restricted stock units. The Form 4 shows the acquisition price as $0, reflecting conversion of vested RSUs into common stock. After the transaction, the filing reports 18,282 shares of common stock beneficially owned by Mr. Krognes and 1,389 RSU-linked derivative shares reported as beneficially owned. The RSU award was originally granted on 08/09/2022 and vested 25% on 06/30/2023, with the remaining 75% vesting in substantially equal monthly installments over the following three years. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Krognes on 10/02/2025.
Helmy Eltoukhy, Co-Chief Executive Officer and director of Guardant Health (GH), reported multiple transactions on 09/30/2025 and 10/01/2025. He had restricted stock units vest that resulted in acquisitions of 4,814 and 23,997 shares (reported as acquisitions at $0), with the company retaining 2,440 and 12,162 shares respectively to satisfy tax-withholding obligations related to the vesting (sales at $62.48 and $62.65). After the reported activity, his beneficial ownership of common stock is shown as 2,149,870 shares following the 10/01/2025 transactions and 119,986 RSU-equivalent shares remaining reported as derivative holdings. The Form 4 is signed by an attorney-in-fact on behalf of Mr. Eltoukhy.
Insider awards to Guardant Health director Alex M. Azar II
Alex M. Azar II, identified as a director of Guardant Health (GH), received equity awards on 09/12/2025. The filing reports a stock option to purchase 10,532 shares with an exercise price of $54.895 and an option term through 09/12/2035. The option and a separate restricted stock unit (RSU) award for 6,604 shares both vest over four years (25% one year after grant, remainder monthly over three years). The Form 4 was signed by an attorney-in-fact on 09/26/2025. The filing shows direct beneficial ownership following the grants: 10,532 option shares and 6,604 RSU shares.
Manuel Hidalgo Medina, a director of Guardant Health, Inc. (GH), reported transactions dated 09/17/2025 showing the acquisition of 232 restricted stock units (RSUs) at $0 pursuant to vesting (Transaction Code M). The Form 4 shows 1,083 shares of common stock held following a separate non-derivative entry and 7,889 shares beneficially owned following the reported derivative transactions. The filing notes the RSU award was granted on July 17, 2024 and vests over four years: 25% vested at the one-year anniversary and the remaining 75% vests monthly over the following three years. The form is signed by an attorney-in-fact on 09/18/2025.
Tariq Musa, a director of Guardant Health, reported two transactions in September 2025. On 09/15/2025 249 restricted stock units (RSUs) vested, converting into 249 common shares and increasing his derivative/underlying holdings. On 09/17/2025 he sold 116 common shares at $55.63 per share, reducing his direct common stock holdings from 7,707 to 7,591 shares. After these transactions, he beneficially owns 7,591 common shares directly and 4,498 shares underlying RSUs.
Myrtle S. Potter, a director of Guardant Health, Inc. (GH), reported an RSU vesting and a subsequent small sale of shares. On 09/15/2025 a restricted stock unit award vested for 68 shares at no cash price. Two days later, on 09/17/2025, the reporting person sold 26 shares at $55.63 per share. Beneficial ownership reported after the sale was 18,281 shares on a direct basis. The filing was executed by attorney-in-fact John G. Saia on 09/17/2025. The RSU award follows a vesting schedule that began with 25% vesting on October 15, 2022, with the remaining 75% vesting monthly over the following three years.
Guardant Health director and Chief Legal Officer John G. Saia reported transactions on Form 4 showing equity activity dated 09/15/2025. The filing discloses that 1,019 restricted stock units vested and were converted into 1,019 shares, of which the company retained a portion to satisfy tax withholding (the filing states the retained amount equaled the tax liability). Also on 09/15/2025 Mr. Saia sold 535 shares at $54.79 per share. After these transactions he beneficially owned 45,432 shares of Guardant Health common stock.
Insider stock changes at Guardant Health (GH): On 09/15/2025 Chief Information Officer Kumud Kalia had 638 restricted stock units vest, resulting in 638 shares issued to her and retained 324 shares that were sold to satisfy tax withholding at a price of $54.79 per share. After these transactions Kalia beneficially owns 19,164 shares of Common Stock. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Chris Freeman, Chief Commercial Officer of Guardant Health (GH), reported insider transactions dated 09/15/2025. The filing shows 1,402 restricted stock units vested and were treated as an acquisition at $0, increasing his beneficial ownership to 50,223 shares before subsequent disposition. The company retained 1,402 shares to satisfy tax withholding related to the vesting. Separately, Freeman disposed of 594 shares at $54.79, leaving him with 49,629 shares beneficially owned after the reported transactions.
Craig Eagle, Chief Medical Officer of Guardant Health, reported transactions on 09/15/2025 related to the vesting of restricted stock units (RSUs) granted June 9, 2023. A tranche of 1,402 shares vested and were delivered at no cash price to the reporting person. To satisfy tax withholding obligations, the company retained 711 shares at an effective withholding price of $54.79 per share.
After these transactions the reporting person beneficially owned 37,482 shares of Guardant Health common stock. The RSU award vests over three years (33% vested June 15, 2024; remaining 67% vests in equal quarterly installments over the following two years). The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Michael Brian Bell, Chief Financial Officer of Guardant Health, reported changes in his beneficial ownership on 09/15/2025. He received two installments of restricted stock units that resulted in 1,233 and 2,039 common shares being issued (transaction codes M) and the company retained 1,233 shares to cover tax withholding. He sold 1,659 shares at $54.79 (transaction code F). Following these transactions he beneficially owned 46,300 shares.